List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9606777/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir. Journal of Thrombosis and Thrombolysis, 2021, 52, 379-382.	2.1	2
2	Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir. Journal of Thrombosis and Thrombolysis, 2021, 52, 379.	2.1	0
3	Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond. Journal of Thrombosis and Thrombolysis, 2021, 52, 408-413.	2.1	О
4	Endogenous Procoagulant Activity in Trauma Patients and Its Relationship to Trauma Severity. TH Open, 2019, 03, e10-e19.	1.4	4
5	Neutralizing and Non-Neutralizing Anti-FVIII Antibodies in Black and White Hemophilia A Subjects: A Natural History Profile. Blood, 2019, 134, 1131-1131.	1.4	3
6	Continuous thrombin generation in whole blood: New applications for assessing activators and inhibitors of coagulation. Analytical Biochemistry, 2018, 551, 19-25.	2.4	21
7	In-depth analysis of clotting dynamics in burn patients. Journal of Surgical Research, 2016, 202, 341-351.	1.6	20
8	Histone H4-Induced Thrombin Generation in Fresh and "Reconstituted" Blood. Blood, 2015, 126, 3494-3494.	1.4	0
9	Platelets do not express the oxidized or reduced forms of tissue factor. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1188-1193.	2.4	17
10	Prothrombin Activation by Platelet-associated Prothrombinase Proceeds through the Prethrombin-2 Pathway via a Concerted Mechanism. Journal of Biological Chemistry, 2012, 287, 38647-38655.	3.4	57
11	Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood, 2012, 120, 3837-3845.	1.4	146
12	Tissue factor controversies. Thrombosis Research, 2012, 129, S5-S7.	1.7	10
13	Dilutional Control of Prothrombin Activation at Physiologically Relevant Shear Rates. Biophysical Journal, 2011, 100, 765-773.	0.5	31
14	Thrombin Generation in Hemorrhage Control and Vascular Occlusion. Circulation, 2011, 124, 225-235.	1.6	67
15	Cellular regulation of blood coagulation: a model for venous stasis. Blood, 2010, 116, 6082-6091.	1.4	23
16	Taking the Thrombin "Fork― Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1293-1299.	2.4	2
17	The effects of flow on the activation of bovine prothrombin by prothrombinase at physiologically relevant shear rates. FASEB Journal, 2010, 24, 835.4.	0.5	1
18	Models of blood coagulation. Blood Cells, Molecules, and Diseases, 2006, 36, 108-117.	1.4	106

2

#	Article	IF	CITATIONS
19	Cleavage of Factor Va Heavy Chain at Arg643 by Thrombin Partially Inactivates the Cofactor Blood, 2006, 108, 1703-1703.	1.4	1
20	Real human tissue factor. FASEB Journal, 2006, 20, A47.	0.5	3
21	The challenge of regulating anticoagulant drugs: Focus on warfarin. American Heart Journal, 2005, 149, S36-S42.	2.7	17
22	Hemophilia and the Dynamics of Hemostasis Blood, 2005, 106, 321-321.	1.4	1
23	The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8918-8923.	7.1	134
24	Membrane-Bound and Soluble Tissue Factor - Fuse and Fire Extinguisher Blood, 2004, 104, 123-123.	1.4	5
25	Demystifying Tissue Factor Blood, 2004, 104, 1936-1936.	1.4	2
26	Quantitative Evaluation of Factor VIII in Factor VIII Products Blood, 2004, 104, 4012-4012.	1.4	0
27	The Dynamics of Thrombin Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 17-25.	2.4	459
28	Response: Mechanism of Action of High-Dose Factor VIIa. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 10-10.	2.4	7
29	Thrombin Formation. Chest, 2003, 124, 4S-10S.	0.8	260
30	Thrombin. Chest, 2003, 124, 1S-3S.	0.8	27
31	Factor V: a combination of Dr Jekyll and Mr Hyde. Blood, 2003, 101, 20-30.	1.4	208
32	Antiplatelet agents in tissue factor–induced blood coagulation. Blood, 2001, 97, 2314-2322.	1.4	88
33	Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation. Circulation, 2001, 103, 2248-2253.	1.6	255
34	Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood, 2000, 95, 1330-1335.	1.4	127
35	"Normal―Thrombin Generation. Blood, 1999, 94, 2169-2178.	1.4	351
36	Noncollagenous Bone Matrix Proteins, Calcification, and Thrombosis in Carotid Artery Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1852-1861.	2.4	145

#	Article	IF	CITATIONS
37	Phenotype and Genotype Expression in Pseudohomozygous Factor VLEIDEN. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 336-342.	2.4	18
38	Blood Coagulation. Alcoholism: Clinical and Experimental Research, 1999, 23, 1111-1113.	2.4	2
39	The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial. Journal of Thrombosis and Thrombolysis, 1998, 5, 53-60.	2.1	13
40	Protein C Activation and Factor Va Inactivation on Human Umbilical Vein Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2765-2775.	2.4	41
41	Factor V Leiden and Thrombophilia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 620-627.	2.4	38
42	The effect of Arg ³⁰⁶ → Ala and Arg ⁵⁰⁶ → Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Science, 1997, 6, 2016-2027.	7.6	46
43	Ultrasensitive Fluorogenic Substrates for Serine Proteases. Thrombosis and Haemostasis, 1997, 78, 1193-1201.	3.4	29
44	Biochemical Prototype for Familial Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2181-2187.	2.4	15
45	Evidence That Meizothrombin Is an Intermediate Product in the Clotting of Whole Blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 754-758.	2.4	35
46	Structure of membrane-bound human factor Va. FEBS Letters, 1994, 351, 330-334.	2.8	32
47	Immunolocalization of noncollagenous bone matrix proteins in lumbar vertebrae from intact and surgically menopausal cynomolgus monkeys. Journal of Bone and Mineral Research, 1993, 8, 71-81.	2.8	44
48	Growth on type I collagen promotes expression of the osteoblastic phenotype in human osteosarcoma MG-63 cells. Journal of Cellular Physiology, 1992, 153, 256-265.	4.1	99
49	A dual beam total internal reflection fluorescence spectrometer for dynamic depth resolved measurements of biochemical liquidâ€solid interface binding reactions in opaque solvents. Review of Scientific Instruments, 1991, 62, 2083-2092.	1.3	15
50	Relationship of glucocorticoid dosage to serum bone gla-protein concentration in patients with rheumatologic disorders. Arthritis and Rheumatism, 1990, 33, 1487-1492.	6.7	58
51	Heterogeneity of human bone. Journal of Bone and Mineral Research, 1990, 5, 933-938.	2.8	91
52	Epitopes of the Human Erythrocyte Ca ²⁺ -Mg ²⁺ ATPase Pump in Human Osteoblast-Like Cell Plasma Membranes*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 1299-1304.	3.6	52
53	A combination of factor Xa and phosphatidylcholineâ€phosphatidylserine vesicles bypasses factor VIII <i>in vivo</i> . British Journal of Haematology, 1988, 69, 491-497.	2.5	16
54	THE COMPLETE AMINO ACID SEQUENCE OF HUMAN FACTOR V. Thrombosis and Haemostasis, 1987, 58, 1088.	3.4	0

#	Article	IF	CITATIONS
55	Megakaryocyte colony growth-supporting activities in human plasma: Modification by platelets and platelet membranes. Journal of Cellular Physiology, 1987, 133, 337-343.	4.1	5
56	Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. Biochemistry, 1979, 18, 996-1003.	2.5	211
57	Multiple Active Forms of Thrombin. Journal of Biological Chemistry, 1971, 246, 6106-6114.	3.4	77
58	The Molecular Weights of Bovine Thrombin and Its Primary Autolysis Products. Journal of Biological Chemistry, 1969, 244, 6555-6557.	3.4	42